Pharmacokinetics of atenolol and its clinical consequences in patients with angina pectoris
Van der Vijgh, W.J.; Majid, P.A.; de Feyter, P.J.; Wardeh, R.; van der Wall, E.E.
International Journal of Clinical Pharmacology Therapy and Toxicology 18(9): 375-377
1980
ISSN/ISBN: 0174-4879 PMID: 7005122 Document Number: 160179
Pharmacokinetics and clinical effects of daily oral doses of 100 mg and 200 mg atenolol, respectively, were studied in patients with angina pectoris by means of a double-blind cross-over randomized study. Half-lives and areas under the curve were of the same magnitude as described earlier for healthy volunteers and hypertensive patients. However, a steady state level was built up during 4-week medication of 100 mg or 200 mg atenolol daily. Intra-patient correlations of plasma levels and reductions in exercising heart rate were moderate (r = 0.56-0.85). Only plasma levels and exercising heart rates revealed significant differences after a 100 mg and 200 mg dose. These findings, together with the remaining clinical observations, demonstrated that a single daily dose of 100 mg atenolol is useful in patients with exercise-induced angina pectoris.